Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;30(6):3206-3214.
doi: 10.1245/s10434-023-13370-1. Epub 2023 Apr 6.

The Landmark Series-Ductal Carcinoma in Situ: The Evolution of Treatment

Amanda L Nash  1   2 , E Shelley Hwang  3   4
Affiliations
Review

The Landmark Series-Ductal Carcinoma in Situ: The Evolution of Treatment

Amanda L Nash et al. Ann Surg Oncol. 2023 Jun.

Abstract

The evolution of ductal carcinoma in situ (DCIS) management has been driven by a parallel evolution in our understanding of its natural history. Early trials established the benefit of adjuvant therapies in all patients with DCIS. In contrast, subsequent studies have stratified patients to determine their eligibility for progressively less invasive and less intensive therapies. Large, randomized trials and meta-analyses have supported this shift away from treating DCIS as an homogenous disease treated with similar intensity to invasive breast cancer. This review describes the landmark studies on which current DCIS management is based.

PubMed Disclaimer

References

    1. Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg. 2003;186(4):337–43. https://doi.org/10.1016/s0002-9610(03)00265-4 . - DOI - PubMed
    1. Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28(23):3762–9. https://doi.org/10.1200/JCO.2009.26.8847 . - DOI - PubMed
    1. Bremer T, Whitworth PW, Patel R, et al. A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk. Clin Cancer Res. 2018;24(23):5895–901. https://doi.org/10.1158/1078-0432.CCR-18-0842 . - DOI - PubMed
    1. Rakovitch E, Gray R, Baehner FL, et al. Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat. 2018;169(2):359–69. https://doi.org/10.1007/s10549-018-4693-2 . - DOI - PubMed - PMC
    1. Worni M, Akushevich I, Greenup R, et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ. J Natl Cancer Inst. 2015;107(12):263. https://doi.org/10.1093/jnci/djv263 . - DOI

MeSH terms

LinkOut - more resources